19 documents

Read All
08:00 , Mar 4, 2013 |  BioCentury  |  Emerging Company Profile

Vedantra: Boosting T cell responses

Vedantra Pharmaceuticals Inc. is developing nanoparticle vaccines that are designed to generate a more potent antibody and T cell response than traditional subunit vaccines. By delivering antigens and immunostimulatory adjuvants in multilayer lipid vesicles, the...
Read More
08:00 , Dec 3, 2012 |  BioCentury  |  Regulation

A tale of two adjuvants

The different results from FDA's panel reviews of Q-Pan H5N1 influenza vaccine from GlaxoSmithKline plc and Heplisav HBV vaccine from Dynavax Technologies Corp. provide three clear messages to companies developing adjuvanted vaccines: the larger the...
Read More
08:00 , Jan 16, 2012 |  BC Week In Review  |  Clinical News

Colby, Juvaris preclinical data

An avian influenza A (H5N1) vaccine adjuvanted with JVRS-100 resulted in 100% survival in mice challenged with 3 H5N1 strains from 2clades vs. 30% survival in mice receiving the vaccine alone. Efficacy was unchanged 14...
Read More
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Colby, Juvaris deal

Colby received exclusive, worldwide rights to develop and commercialize Juvaris' Cationic Lipid-DNA Complex (CLDC) technology and JVRS-100 for non-veterinary use. Colby will develop the products to target infectious diseases and inflammation. Juvaris will receive...
Read More
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

Juvaris preclinical data

In mouse models of AML, JVRS-100 significantly increased survival vs. untreated controls. Furthermore, mice whose initial leukemia was successfully treated by JVRS-100 survived significantly longer in response to a secondary leukemic challenge even after treatment...
Read More
07:00 , Jul 12, 2010 |  BC Week In Review  |  Clinical News

Juvaris preclinical data

JVRS-100 plus a crude membrane fraction of a weakened strain of Francisella tularensis given to mice 3 days prior to infection with a lethal dose of virulent F. tularensis resulted in a 66% survival rate...
Read More
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

JVRS-100: Phase II started

Juvaris began a double-blind Phase II trial to compare Fluzone with or without 3.75, 7.5 or 25 ug of intramuscular JVRS-100 adjuvant in about 472 elderly volunteers. Fluzone is a trivalent influenza vaccine marketed...
Read More
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

Juvaris preclinical data

In mice, JVRS-100 enhanced immunogenicity of the A/Vietnam/1203/04 H5N1 influenza vaccine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France) when challenged with lethal doses of drifted strains of avian influenza A (H5N1). Specifically, as...
Read More
08:00 , Nov 2, 2009 |  BioCentury  |  Product Development

Mimicking viral infections

Marketed vaccine adjuvants are effective at increasing the antibody response to the vaccine antigen, but few non-replicating adjuvants generate strong T cell responses, which limits their effectiveness in the elderly and against many infectious agents. Juvaris...
Read More
00:11 , Sep 18, 2009 |  BC Extra  |  Financial News

Juvaris completes first close in B round

Juvaris BioTherapeutics Inc. (Burlingame, Calif.) raised an undisclosed amount in the first close of a series B round led by new investor SV Life Sciences with participation from existing investor Kleiner Perkins Caufield & Byers....
Read More